Immunotherapy in ovarian cancer

Curr Probl Cancer. 2017 Jan-Feb;41(1):48-63. doi: 10.1016/j.currproblcancer.2016.11.003. Epub 2016 Nov 15.

Abstract

Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor-modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery.

Keywords: Immunotherapy; ovarian cancer.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Cancer Vaccines / therapeutic use*
  • Cell Cycle Checkpoints / immunology
  • Female
  • Humans
  • Immunotherapy / methods*
  • Immunotherapy / trends
  • Immunotherapy, Adoptive / methods
  • Molecular Targeted Therapy / methods
  • Ovarian Neoplasms / immunology
  • Ovarian Neoplasms / therapy*

Substances

  • Antibodies, Monoclonal
  • Cancer Vaccines